Member of Lyonbiopole
Development of antivirals EBV infections. Main objective is the control of the activation and immortalization of B cells following infection with EBV for providing new treatment for EBV-associated diseases that include post-transplantation lymphoproliferative diseases, lymphomas, and multiple sclerosis.
Strategic application domain: Human Medicine
Application market: Hematology, Infectious Diseases, Neurology & Mental Health Disorders
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Small Molecules
Created on oct. 9th, 2020 - 2 employees
Address
321 avenue Tony Garnier 69007 Lyon
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.